On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
Research entry: inclusion is for identification, not approval or a recommendation to use it. Verify the exact product and current US status with a pharmacist.
Ghrelin-pathway research
Ipamorelin is described as a ghrelin mimetic. The trial investigated whether this pathway could affect gastrointestinal recovery following surgery. That biological rationale should not be confused with successful treatment on the trial’s main endpoint. [1]
What the evidence shows
What the human trial tested
A randomized trial tested intravenous ipamorelin after bowel surgery. It found no significant difference from placebo on its key or secondary efficacy analyses. This was not a sleep or fitness trial. [1]
Population and endpoint
The bowel-resection trial enrolled 117 patients and analyzed 114. It evaluated recovery of gastrointestinal function after surgery, rather than wellness, sleep, or body composition. A result in this monitored intravenous setting cannot determine the effect of a community protocol. [1]
What remains unknown
This study does not establish benefits or safety for subcutaneous wellness use or for combinations.
Safety
Route-specific uncertainty
FDA notes serious events in an intravenous study and insufficient safety information for certain other injectable routes. This does not establish that ipamorelin caused those events. [2]
Intravenous study versus other routes
The cited trial used an intravenous study preparation in postoperative patients. It provides no verified universal reconstitution or storage instructions for subcutaneous wellness products. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [3]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [4]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Does stimulating a hormone establish better recovery?
No. The relevant clinical outcome needs to be measured and compared with a suitable control. A mechanism alone does not show that a user will sleep, heal, or perform better.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients2014 · randomized human trial · PMID 25331030
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksFDA · safety information · accessed September 2026
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.